Advertisement
Person › Details
Marc Martinell (Minoryx Therapeutics S.L.)
Martinell, Marc (Minoryx Therapeutics SL 201404 CEO + Co-Founder)
Organisation | Minoryx Therapeutics S.L. | |
Group | Minoryx (Group) | |
Product | DRUGS, ORPHAN | |
Product 2 | leriglitazone (MIN-102) | |
Record changed: 2022-06-02 |
Advertisement
More documents for Marc Martinell
- [1] Minoryx Therapeutics S.L.. (5/31/22). "Press Release: Minoryx Raises €51 Million to Support Marketing Authorization Application and Launch Preparations for X-linked Adrenoleukodystrophy (X-ALD) therapy". Mataró, Barcelona....
- [2] Minoryx Therapeutics S.L.. (3/12/19). "Press Release: Minoryx Therapeutics Appoints Didier Le Normand as Group Chief Financial Officer (CFO) and General Manager of Its Belgian Subsidiary". Mataró, Barcelona & Charleroi....
- [3] Minoryx Therapeutics S.L.. (1/15/19). "Press Release: Minoryx Therapeutics Extends Its Activities in Belgium". Mataró, Barcelona & Charleroi....
- [4] Minoryx Therapeutics S.L.. (12/13/18). "Press Release: Minoryx Therapeutics Announces Early Completion of Patient Randomization in the ADVANCE Trial – a Phase 2/3 Clinical Study of MIN-102 in X-ALD Patients". Mataró, Barcelona....
- [5] Minoryx Therapeutics S.L.. (2/22/17). "Press Release: Minoryx Therapeutics Receives Orphan Drug Designation from the US FDA for Its Lead Candidate MIN-102". Mataró, Barcelona....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top